A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia

Inclusion Criteria:

- Diagnosis of relapsing/refractory or previously untreated chronic lymphocytic leukemia

- Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to
(
- Adequate bone marrow function

- Adequate coagulation, renal and hepatic function

- For all participants, agreement to remain abstinent or use contraceptive methods that
result in a failure rate of less than (<) 1% per year during the treatment period and
for at least 90 days (30 days for women) after the last dose of venetoclax or 18
months after the last dose of obinutuzumab, whichever is longer

Exclusion Criteria:

- Participants who have undergone allogenic stem cell transplant are ineligible unless
they meet the following criteria, a) participants who are off all immunosuppressive
therapy, b) participants who have no signs and/or symptoms of acute or chronic graft
versus host disease, or c) participants must have appropriate hematology counts

- Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C

- Uncontrolled autoimmune hemolytic anemia or thrombocytopenia

- Investigational or anti-cancer therapy within 5 half-lives prior to the first dose of
study drug

- History of significant renal, neurologic, psychiatric, endocrinologic, metabolic,
immunologic, cardiovascular, or hepatic disease